New Crohn’s Indication Puts Janssen’s Stelara On Equal Ground With Anti-TNFs

J&J’s Janssen Biotech subsidiary won FDA approval for the IL-12/IL-23 inhibitor Stelara to treat Crohn’s disease, giving it a second-line position alongside anti-TNF therapies for patients in need of new options.